Showing 361 - 380 results of 926 for search '"Lung cancer"', query time: 0.11s Refine Results
  1. 361
  2. 362
  3. 363
  4. 364
  5. 365

    Beyond the Dual Paraneoplastic Syndromes of Small-Cell Lung Cancer with ADH and ACTH Secretion: A Case Report with Literature Review and Future Implications by Krishna Adit Agarwal, Myat Han Soe

    Published 2018-01-01
    “…We present a case of small-cell lung cancer (SCLC) with syndrome of inappropriate antidiuretic hormone secretion (SIADH) in which serum sodium gradually normalized with the onset of hypertension, refractory hypokalemia, and chloride-resistant metabolic alkalosis due to ectopic adrenocorticotrophic hormone (ACTH) secretion (EAS). …”
    Get full text
    Article
  6. 366

    Perioperative Exhaled Nitric Oxide as an Indicator for Postoperative Pneumonia in Surgical Lung Cancer Patients: A Prospective Cohort Study Based on 183 Cases by Gui-Xian Liu, Yue Yang, Lei Chen, Mi-Qi Gu, Jin-Tao He, Xin Wang

    Published 2022-01-01
    “…This study is conducted to investigate the correlation between perioperative fractional exhaled nitric oxide and postoperative pneumonia (POP) and the feasibility of perioperative FeNO for predicting POP in surgical lung cancer patients. Methods. Patients who were diagnosed with non-small-cell lung cancer (NSCLC) were prospectively analyzed, and the relationship between perioperative FeNO and POP was evaluated based on patients’ basic characteristics and clinical data in the hospital. …”
    Get full text
    Article
  7. 367
  8. 368
  9. 369

    Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy by Zheng-Hao Ye, Hao Long, Ze-Rui Zhao

    Published 2022-01-01
    “…Neoadjuvant immunotherapy is promising for locally advanced non-small-cell lung cancer (NSCLC). The in situ immune patterns, as a predictor of PD-1/PD-L1 blockade outcomes, of the primary tumor (PT) and metastatic lymph nodes (mLNs) are unknown. …”
    Get full text
    Article
  10. 370
  11. 371

    Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis by Luqing Zhao, Zhiting Zhao, Xiaoqi Yan, Fei Wu, Ning Sun, Renhong Guo, Shaorong Yu, Xiao Hu, Jifeng Feng

    Published 2024-01-01
    “…Based on PACIFIC trial, durvalumab as consolidation therapy following concurrent chemoradiotherapy (cCRT) has been a new standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). In clinical applications, there are heterogeneous adjustments or novel strategies following specialized discussions in experienced multidisciplinary teams. …”
    Get full text
    Article
  12. 372

    Characterization of H460R, a Radioresistant Human Lung Cancer Cell Line, and Involvement of Syntrophin Beta 2 (SNTB2) in Radioresistance by Chang-Nim Im, Byeong Mo Kim, Eun-Yi Moon, Da-Won Hong, Joung Whan Park, Sung Hee Hong

    Published 2013-12-01
    “…H460R cells could be helpful in in vitro systems for elucidating the molecular mechanisms of and discovering drugs to overcome radioresistance in lung cancer therapy.…”
    Get full text
    Article
  13. 373

    Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis by Xiaojun Yang, Yihong Zeng, Qinquan Tan, Zhihua Huang, Jun Jia, Guanming Jiang

    Published 2022-01-01
    “…Immune checkpoint inhibitors (ICIs) are widely used to treat local or metastatic lung cancer. However, the efficacy of ICI in patients with brain metastases (BM) from lung cancer is unknown. …”
    Get full text
    Article
  14. 374
  15. 375
  16. 376
  17. 377
  18. 378
  19. 379
  20. 380

    Metastatic Non-Small-Cell Lung Cancer in the Setting of Unilateral Agenesis of the Left Pulmonary Artery: A Case Report and Comprehensive Literature Review by John Agzarian, Jakub Kadlec, Lori Whitehead, Yaron Shargall

    Published 2019-01-01
    “…We present the first reported case of ipsilateral metastatic non-small-cell lung cancer- (NSCLC-) associated UAPA in a 47-year-old patient with ventilator-dependent hypoxic respiratory failure and bronchorrhea, who had been lost to follow-up for 8 years. …”
    Get full text
    Article